Rice Hall James & Associates LLC Sells 730,288 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Rice Hall James & Associates LLC reduced its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 73.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 268,337 shares of the company's stock after selling 730,288 shares during the quarter. Rice Hall James & Associates LLC owned approximately 0.58% of Pacira BioSciences worth $4,038,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Texas Permanent School Fund Corp increased its holdings in shares of Pacira BioSciences by 1.4% in the 1st quarter. Texas Permanent School Fund Corp now owns 40,642 shares of the company's stock valued at $1,188,000 after acquiring an additional 543 shares during the last quarter. Duality Advisers LP increased its stake in Pacira BioSciences by 1.8% during the first quarter. Duality Advisers LP now owns 34,784 shares of the company's stock valued at $1,016,000 after purchasing an additional 605 shares during the last quarter. Inspire Investing LLC raised its holdings in shares of Pacira BioSciences by 5.9% during the first quarter. Inspire Investing LLC now owns 12,131 shares of the company's stock worth $354,000 after purchasing an additional 675 shares during the period. ProShare Advisors LLC lifted its position in shares of Pacira BioSciences by 8.0% in the 1st quarter. ProShare Advisors LLC now owns 12,461 shares of the company's stock worth $364,000 after buying an additional 924 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Pacira BioSciences by 229.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after buying an additional 932 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Insider Activity at Pacira BioSciences

In other news, CEO Frank D. Lee acquired 8,264 shares of the business's stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average cost of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the acquisition, the chief executive officer now owns 107,784 shares in the company, valued at approximately $1,304,186.40. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have acquired 11,176 shares of company stock valued at $136,240. Company insiders own 6.40% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. HC Wainwright cut their target price on shares of Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating on the stock in a report on Monday, August 12th. Needham & Company LLC cut their price target on Pacira BioSciences from $43.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, August 12th. JPMorgan Chase & Co. restated an "underweight" rating and set a $10.00 price objective (down from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Piper Sandler cut Pacira BioSciences from an "overweight" rating to a "neutral" rating and cut their target price for the company from $42.00 to $11.00 in a research note on Monday, August 12th. Finally, Jefferies Financial Group boosted their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $24.20.

Pacira BioSciences Trading Down 0.2 %

Shares of Pacira BioSciences stock traded down $0.03 on Friday, reaching $16.57. 466,519 shares of the company were exchanged, compared to its average volume of 868,019. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $35.95. The firm has a market capitalization of $764.32 million, a price-to-earnings ratio of 12.95 and a beta of 0.84. The stock has a fifty day moving average price of $15.34 and a 200-day moving average price of $21.39.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The company had revenue of $178.02 million during the quarter, compared to analyst estimates of $173.31 million. On average, analysts expect that Pacira BioSciences, Inc. will post 2.2 EPS for the current year.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.